A Phase 3 interventional study of DPT-IPV-Hib (Combined Vaccine) in Immunization, sponsored by Tanabe Pharma Corporation. Completed at 3 sites in Japan. Open to participants aged 2 Months to 43 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-06.
Sponsored by Tanabe Pharma Corporation · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the safety and efficacy of an intramuscular injection of BK1310 in healthy infants.
176 studies on the registry are indexed under Haemophilus Infections; 5 are open to participants now.
This study's enrollment of 33 is below the median of 458 across 163 interventional studies indexed under Haemophilus Infections.
Browse Haemophilus Infections studies →Tanabe Pharma Corporation is the lead sponsor of 92 studies on the registry; 1 is open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: DPT-IPV-Hib (Combined Vaccine)
Drug page: Vaccines, Combined
0.5mL, intramuscular injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
Also known as: BK1310
Antibody Prevalence Rate Against Anti-PRP With 1 μg/mL or Higher, Diphtheria Toxin, Pertussis, Tetanus Toxin, and Polio Virus, Defined as the Percentage of Participants With the Antibody Against Anti-PRP
Antibody prevalence rate is defined as the percentage of participants whose criteria of each antibody titer: Anti-diphtheria antibody concentrations: \>=0.1 IU/mL, Anti-PT antibody concentrations: \>=10.0 EU/mL, Anti-FHA antibody concentrations: \>=10.0 EU/mL, Anti-tetanus antibody concentrations: \>=0.01 IU/mL, Anti-poliovirus serotype 1,2 and 3 antibody titers (fold) \>=8
Time frame: 4 weeks after the primary immunization (Visit 4)
Anti-PRP Antibody Prevalence Rate With 0.15 μg/mL or Higher, Defined as the Percentage of Participants With the Anti-PRP Antibody
Time frame: 4 weeks after the primary immunization (Visit 4)
Geometric Mean Antibody Titer of Anti-PRP Antibody
Time frame: 4 weeks after the primary immunization (Visit 4)
Anti-PRP Antibody Prevalence Rate With 1 μg/mL or Higher, Defined as the Percentage of Participants With the Anti-PRP Antibody
Time frame: 4 weeks after the booster dose (Visit 6)
Anti-PRP Antibody Prevalence Rate With 0.15 μg/mL or Higher, Defined as the Percentage of Participants With the Anti-PRP Antibody
Time frame: 4 weeks after the booster dose (Visit 6)
Geometric Mean Antibody Titer of Anti-PRP Antibody
Time frame: 4 weeks after the booster dose (Visit 6)
Geometric Mean Antibody Titer Against Diphtheria Toxin
Time frame: 4 weeks after the primary immunization (Visit 4)
Geometric Mean Antibody Titer Against Pertussis (PT)
Time frame: 4 weeks after the primary immunization (Visit 4)
Geometric Mean Antibody Titer Against Pertussis (FHA)
Time frame: 4 weeks after the primary immunization (Visit 4)
Geometric Mean Antibody Titer Against Tetanus Toxin
Time frame: 4 weeks after the primary immunization (Visit 4)
Fold Change in Geometric Mean Antibody Titer Against Polio Virus
Time frame: Baseline and 4 weeks after the primary immunization (Visit 4)
Antibody Prevalence Rate Against Diphtheria Toxin, Pertussis, Tetanus Toxin, and Polio Virus, Defined as the Percentage of Participants With the Antibody Against Diphtheria Toxin, Pertussis, Tetanus Toxin, and Polio Virus
Antibody prevalence rate is defined as the percentage of participants whose criteria of each antibody titer: Anti-diphtheria antibody concentrations: \>=0.1 IU/mL, Anti-PT antibody concentrations: \>=10.0 EU/mL, Anti-FHA antibody concentrations: \>=10.0 EU/mL, Anti-tetanus antibody concentrations: \>=0.01 IU/mL, Anti-poliovirus serotype 1,2 and 3 antibody titers (fold) \>=8
Time frame: 4 weeks after the booster dose (Visit 6)
Geometric Mean Antibody Titer Against Diphtheria Toxin
Time frame: 4 weeks after the booster dose (Visit 6)
Geometric Mean Antibody Titer Against Pertussis (PT)
Time frame: 4 weeks after the booster dose (Visit 6)
Geometric Mean Antibody Titer Against Pertussis (FHA)
Time frame: 4 weeks after the booster dose (Visit 6)
Geometric Mean Antibody Titer Against Tetanus Toxin
Time frame: 4 weeks after the booster dose (Visit 6)
Fold Change in Geometric Mean Antibody Titer Against Polio Virus
Time frame: Baseline and 4 weeks after the primary immunization (Visit 6)
| Milestone | BK1310 |
|---|---|
| Started | 33 |
| Completed | 33 |
| Not completed | 0 |
Antibody prevalence rate is defined as the percentage of participants whose criteria of each antibody titer: Anti-diphtheria antibody concentrations: \>=0.1 IU/mL, Anti-PT antibody concentrations: \>=10.0 EU/mL, Anti-FHA antibody concentrations: \>=10.0 EU/mL, Anti-tetanus antibody concentrations: \>=0.01 IU/mL, Anti-poliovirus serotype 1,2 and 3 antibody titers (fold) \>=8
| percentage of participants | BK1310 |
|---|---|
| Antibody prevalence rate against anti-PRP with 1 μg/mL or higher | 97.0 (84.2 to 99.9) |
| Antibody prevalence rate against diphtheria toxin | 93.9 (79.8 to 99.3) |
| Antibody prevalence rate against pertussis (PT) | 100.0 (89.4 to 100.0) |
| Antibody prevalence rate against pertussis (FHA) | 97.0 (84.2 to 99.9) |
| Antibody prevalence rate against tetanus toxin | 100.0 (89.4 to 100.0) |
| Antibody prevalence rate against polio virus serotype 1 | 100.0 (89.4 to 100.0) |
| Antibody prevalence rate against polio virus serotype 2 | 100.0 (89.4 to 100.0) |
| Antibody prevalence rate against polio virus serotype 3 | 100.0 (89.4 to 100.0) |
| percentage of participants | BK1310 |
|---|---|
| Anti-PRP Antibody Prevalence Rate With 0.15 μg/mL or Higher, Defined as the Percentage of Participants With the Anti-PRP Antibody | 100.0 (89.4 to 100.0) |
| µg/mL | BK1310 |
|---|---|
| Geometric Mean Antibody Titer of Anti-PRP Antibody | 13.522 (8.628 to 21.192) |
| percentage of participants | BK1310 |
|---|---|
| Anti-PRP Antibody Prevalence Rate With 1 μg/mL or Higher, Defined as the Percentage of Participants With the Anti-PRP Antibody | 100.0 (89.4 to 100.0) |
| percentage of participants | BK1310 |
|---|---|
| Anti-PRP Antibody Prevalence Rate With 0.15 μg/mL or Higher, Defined as the Percentage of Participants With the Anti-PRP Antibody | 100.0 (89.4 to 100.0) |
| µg/mL | BK1310 |
|---|---|
| Geometric Mean Antibody Titer of Anti-PRP Antibody | 28.509 (20.866 to 38.952) |
| IU/mL | BK1310 |
|---|---|
| Geometric Mean Antibody Titer Against Diphtheria Toxin | 1.0818 (0.7157 to 1.6352) |
| EU/mL | BK1310 |
|---|---|
| Geometric Mean Antibody Titer Against Pertussis (PT) | 128.03 (106.09 to 154.51) |
| EU/mL | BK1310 |
|---|---|
| Geometric Mean Antibody Titer Against Pertussis (FHA) | 53.64 (44.01 to 65.40) |
| IU/mL | BK1310 |
|---|---|
| Geometric Mean Antibody Titer Against Tetanus Toxin | 0.3068 (0.2091 to 0.4502) |
| fold change | BK1310 |
|---|---|
| Geometric mean antibody titer against polio virus serotype 1 | 551.06 (348.74 to 870.74) |
| Geometric mean antibody titer against polio virus serotype 2 | 1510.29 (1046.26 to 2180.11) |
| Geometric mean antibody titer against polio virus serotype 3 | 1290.16 (937.99 to 1774.55) |
Antibody prevalence rate is defined as the percentage of participants whose criteria of each antibody titer: Anti-diphtheria antibody concentrations: \>=0.1 IU/mL, Anti-PT antibody concentrations: \>=10.0 EU/mL, Anti-FHA antibody concentrations: \>=10.0 EU/mL, Anti-tetanus antibody concentrations: \>=0.01 IU/mL, Anti-poliovirus serotype 1,2 and 3 antibody titers (fold) \>=8
| percentage of participants | BK1310 |
|---|---|
| Antibody prevalence rate against diphtheria toxin | 100.0 (89.4 to 100.0) |
| Antibody prevalence rate against pertussis (PT) | 100.0 (89.4 to 100.0) |
| Antibody prevalence rate against pertussis (FHA) | 100.0 (89.4 to 100.0) |
| Antibody prevalence rate against tetanus toxin | 100.0 (89.4 to 100.0) |
| Antibody prevalence rate against polio virus serotype 1 | 100.0 (89.4 to 100.0) |
| Antibody prevalence rate against polio virus serotype 2 | 100.0 (89.4 to 100.0) |
| Antibody prevalence rate against polio virus serotype 3 | 100.0 (89.4 to 100.0) |
| IU/mL | BK1310 |
|---|---|
| Geometric Mean Antibody Titer Against Diphtheria Toxin | 9.6485 (7.2551 to 12.8316) |
| EU/mL | BK1310 |
|---|---|
| Geometric Mean Antibody Titer Against Pertussis (PT) | 173.17 (140.90 to 212.84) |
| EU/mL | BK1310 |
|---|---|
| Geometric Mean Antibody Titer Against Pertussis (FHA) | 114.19 (89.14 to 146.28) |
| IU/mL | BK1310 |
|---|---|
| Geometric Mean Antibody Titer Against Tetanus Toxin | 1.8293 (1.2107 to 2.7640) |
| fold change | BK1310 |
|---|---|
| Geometric mean antibody titer against polio virus serotype 1 | 1642.66 (1162.23 to 2321.68) |
| Geometric mean antibody titer against polio virus serotype 2 | 8910.01 (6877.46 to 11543.27) |
| Geometric mean antibody titer against polio virus serotype 3 | 5000.58 (3839.01 to 6513.60) |
Collected over Through study completion, an average of 1 year. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BK1310 | 0/33 (0%) | 2/33 (6.1%) | 33/33 (100%) |
| Event | BK1310 |
|---|---|
| BronchiolitisInfections and infestations | 1/33 |
| BronchitisInfections and infestations | 1/33 |
| Exanthema subitumInfections and infestations | 1/33 |
| Event | BK1310 |
|---|---|
| PyrexiaGeneral disorders | 25/33 |
| Injection site erythemaGeneral disorders | 16/33 |
| CryingGeneral disorders | 11/33 |
| Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders | 11/33 |
| HypersomniaNervous system disorders | 10/33 |
| InsomniaPsychiatric disorders | 7/33 |
| Injection site swellingGeneral disorders | 6/33 |
| Injection site indurationGeneral disorders | 5/33 |
| BronchitisInfections and infestations | 5/33 |
| ConjunctivitisInfections and infestations | 5/33 |
| Age, Customized(Participants) | BK1310 |
|---|---|
| >=2 and <3 months | 27 |
| >=3 months | 6 |
| Sex: Female, Male(Participants) | BK1310 |
|---|---|
| Female | 10 |
| Male | 23 |
| Race/Ethnicity, Customized(Participants) | BK1310 |
|---|---|
| Asian (Japanese) | 33 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2017 to primary completion in Nov 2017, 4 months.
Results were first posted in Jan 2025, 7 years 2 months after primary completion.
Of 23 industry-sponsored phase 3 interventional studies under Haemophilus Infections, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 21. This study's 4 months is below that.
Counting every sponsor, half of 23 studies reached it within 11 months; a quarter within 5 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vaccines, Combined